Please ensure Javascript is enabled for purposes of website accessibility

Why Pliant Therapeutics Stock Is Surging Today

By Cory Renauer – Sep 7, 2021 at 12:07PM

Key Points

  • Pliant Therapeutics reported positive data from a phase 2 trial with its experimental fibrosis therapy, PLN-74809, this morning.
  • Data from four patients given the anti-fibrosis candidate suggest it works as intended, at least on a molecular level.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A positive phase 2 clinical trial readout was a positive step in the right direction for this biotech start-up.

What happened

Shares of Pliant Therapeutics (PLRX -5.84%), a clinical-stage biotech company, are on the move following a clinical trial readout for its lead candidate, PLN-74809. Investors impressed with the positive results drove the stock 23% higher shortly after the market opened this morning. The stock was up 11.1% as of 11:23 a.m. EDT on Tuesday.

So what 

Pliant's developing PLN-74809 for people who experience progressive lung scarring that occurs for reasons medicine can't explain yet. Idiopathic pulmonary fibrosis (IPF) is lethal, but there aren't any available treatments to prevent its progression.

Crowd of cheering doctors.

Image source: Getty Images.

Treatment with PLN-74809 should disrupt a specific pair of proteins involved in the formation of scar tissue. The biotech stock is rising today in response to clinical trial data that says it did just this for a handful of IPF patients. 

All four patients evaluated with a PET scan showed more than 50% target engagement after receiving one dose. Two of the patients who received higher doses exhibited more than 90% target engagement. 

Now what

It's important to note that PLN-74809 is a novel drug candidate with an all-new mechanism of action. We still can't say for sure if the target is a valid one. We'll find out once the company reads out the results from an ongoing phase 2 trial called Integris-IPF.

The Integris-IPF study, meant to enroll 84 patients, began in March 2020 and is only treating patients for 12 weeks before measuring PLN-74809's ability to improve their lung capacity. If PLN-74809 had what it takes to quickly improve outcomes for people with this slowly progressing disease, I think we would have heard about it already. It's probably best to watch the next chapter of this risky drugmaker's story play out from a safe distance.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pliant Therapeutics, Inc. Stock Quote
Pliant Therapeutics, Inc.
PLRX
$18.38 (-5.84%) $-1.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.